23-Apr-2024
No headlines found.
Globe Newswire (Thu, 11-Apr 8:00 AM ET)
Collegium to Participate in 23rd Annual Needham Virtual Healthcare Conference
Globe Newswire (Wed, 3-Apr 8:00 AM ET)
Collegium Reports Record Fourth Quarter and Full-Year 2023 Financial Results
Globe Newswire (Thu, 22-Feb 4:09 PM ET)
Collegium to Report Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024
Globe Newswire (Thu, 8-Feb 8:00 AM ET)
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
Collegium Pharmaceutical trades on the NASDAQ stock market under the symbol COLL.
As of April 23, 2024, COLL stock price climbed to $35.94 with 430,455 million shares trading.
COLL has a beta of 0.68, meaning it tends to be less sensitive to market movements. COLL has a correlation of 0.08 to the broad based SPY ETF.
COLL has a market cap of $1.15 billion. This is considered a Small Cap stock.
Last quarter Collegium Pharmaceutical reported $150 million in Revenue and $1.58 earnings per share. This beat revenue expectation by $2 million and exceeded earnings estimates by $.92.
In the last 3 years, COLL stock traded as high as $40.95 and as low as $14.04.
The top ETF exchange traded funds that COLL belongs to (by Net Assets): CALF, IJR, VTI, IWM, VXF.
COLL has outperformed the market in the last year with a return of +55.8%, while the SPY ETF gained +24.3%. In the last 3 month period, COLL beat the market returning +9.0%, while SPY returned +4.6%. However, in the most recent 2 weeks COLL has underperformed the stock market by returning -7.3%, while SPY returned -2.6%.
COLL support price is $33.90 and resistance is $35.58 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that COLL stock will trade within this expected range on the day.